{"id":25459,"date":"2020-03-11T15:51:43","date_gmt":"2020-03-11T13:51:43","guid":{"rendered":"https:\/\/www.asperbio.com\/?page_id=25459"},"modified":"2020-05-28T16:18:02","modified_gmt":"2020-05-28T13:18:02","slug":"naisepoolse-viljatusega-seotud-geenide-sekveneerimine","status":"publish","type":"page","link":"https:\/\/www.asperbio.com\/et\/asper-reprogenetics-testid-2\/naisepoolse-viljatusega-seotud-geenide-sekveneerimine\/","title":{"rendered":"Naisepoolse viljatusega seotud geenide sekveneerimine"},"content":{"rendered":"<h2 style=\"padding-left: 5px;\"><span style=\"color: #e63458;\">Naisepoolse viljatusega seotud geenide sekveneerimine<\/span><\/h2>\n<div class=\"sm_post_content\" style=\"background: url('https:\/\/www.asperbio.com\/wp-content\/uploads\/t-roosa.png') repeat-y; padding-left: 40px;\">\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Geenid:<\/strong><\/td>\n<td><em>ANOS1, AR, AXL, BMP15, BMP4, CASR, CCDC141, CFTR, CLPP, CPEB1, DUOX1, DUOX2, DUOXA2, DUSP6, EIF2B1, EIF2B2, EIF2B4, EIF2B5, EIF4ENIF1, ERCC6, ESR1, ESR2, F2, F5, FEZF1, FGF17, FGF8, FGFR1, FIGLA, FLRT3, FMR1 <\/em>(k.a. CGG trinukleotiidsed kordusj\u00e4rjestused)<em>, FOXE1, FOXL2, FSHB, FSHR, GCM2, GDF9, GHR, GLIS3, GNAS, GNRH1, GNRHR, HARS2, HESX1, HFM1, HSD17B4, HS6ST1, IGSF1, IL17RD, INHA, IRS4, IYD, KISS1, KISS1R, LARS2, LHCGR, LHB, LHX3, LHX4, LHX8, MCM8, MCM9, MRPS22, MSH5, MTHFR, NANOS3, NKX2-1, NKX2-5, NLRP2, NLRP5, NOBOX, NR0B1, NR5A1, NSMF, NUP107, OTX2, PADI6, PATL2, PAX8, PDE3A, PLCZ1, POLR3B, POU1F1, PROC, PROK2, PROKR2, PROP1, PROS1, PSMC3IP, SECISBP2, SEMA3A, SERPINC1, SERPINE1, SLC26A4, SLC5A5, SMC1B, SOHLH1, SOX10, SOX2, SOX3, SPIDR, SPRY4, SRA1, STAG3, SYCE1, SYCE3, SYCP3, TAC3, TACR3, TBL1X, TG, THBD, THRA, THRB, TPO, TRH, TRHR, TSHB, TSHR, TTF1, TUBB8, WDR11, WEE2, WNT4, WT1, ZP1, ZP2, ZP3<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #e63458; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Metoodika:<\/strong><\/td>\n<td>Kodeeriva piirkonna sekveneerimine (NGS).<br \/>\nKoopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #e63458; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Testi valmimisaeg:<\/strong><\/td>\n<td>6-9\u00a0n\u00e4dalat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #e63458; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>N\u00f5uded proovi-materjalile:<\/strong><\/td>\n<td>2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti)<\/p>\n<p>1\u00b5g DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l<br \/>\nDNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis olema detekteeritav \u00fche tervikliku b\u00e4ndina.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #e63458; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Tellimine:<\/strong><\/td>\n<td>Proovimaterjal saata koos <a href=\"https:\/\/www.asperbio.com\/wp-content\/uploads\/Asper-Reprogenetics-saatekiri.doc\"><span style=\"color: #e63458;\"><strong>saatekirjaga<\/strong><\/span><\/a> Asper Biogene laborisse<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #e63458; height: 2px; border: none; width: 100%;\" \/>\n<\/div>\n<p><b>N\u00e4idustused geenitesti tegemiseks:<\/b><\/p>\n<p>1. Viljatuse kahtlus naistel, kellel on kliinilised anal\u00fc\u00fcsid ja kar\u00fcot\u00fcpiseerimine teostatud<br \/>\n2. Munasarjade d\u00fcsfunktsioon ja korduv raseduse katkemine<br \/>\n3. Viljatusravi protseduure plaanivate paaride testimine<br \/>\n4. P\u00e4riku haigusriski hindamine kunstliku viljastamise teel s\u00fcndival lapsel<\/p>\n<p style=\"text-align: justify;\"><strong>Naisepoolne viljatus<\/strong> moodustab u 35% k\u00f5igist viljatuse p\u00f5hjustest. Naisepoolse viljatuse p\u00f5hjused v\u00f5ivad varieeruda suures ulatuses, h\u00f5lmates nii munasarjade arengut, oots\u00fc\u00fctide k\u00fcpsemist ja viljastumise v\u00f5imalikkust m\u00f5jutavaid tegureid kui ka viljastatud munaraku potentsiaali arenemiseks, implantatsiooniks ja loote arenguks.<\/p>\n<p style=\"text-align: justify;\">Naisepoolne viljatus v\u00f5ib olla seotud ka haigustega nagu <strong>pol\u00fcts\u00fcstiliste munasarjade s\u00fcndroom<\/strong> ja <strong>endometrioos<\/strong> ning keskonna tegurite ja elustiiliga. Pol\u00fcts\u00fcstiliste munasarjade s\u00fcndroom on sagedaseim viljatuse p\u00f5hjus. Tegemist on kompleksse hormonaalse ja metaboolse haigusega, v\u00f5ib esineda 5-20% reproduktiivses eas naistel. Haigusele on iseloomulik <strong>h\u00fcperandrogenism<\/strong>, <strong>oligo- ja\/v\u00f5i anovulatsioon<\/strong>, pol\u00fcts\u00fcstilised munasarjad ja gonadotroopilised k\u00f5rvalekalded. Endometrioos ohustab 7-10% naisi ja on samuti \u00fcks viljatusep\u00f5hjustest.<\/p>\n<p style=\"text-align: justify;\">Geneetilised naisepoolse viljatusega seotud muutused v\u00f5ivad olla ulatuslikud kromosomaalsed k\u00f5rvalekalded ja submikroskoopilised kromosoomi deletsioonid ning duplikatsioonid. V\u00f5ib esineda ka DNA j\u00e4rjestuses olevaid muutusi oogeneesiga, munarakkude reservi s\u00e4ilitamisega, hormonaalsete signaalide ning naissuguorganite anatoomilise ja funktsionaalse arenguga seotud geenides. Geneetilised tegurid moodustavad u 10% naisepoolse viljatuse p\u00f5hjustest.<\/p>","protected":false},"excerpt":{"rendered":"<p>Naisepoolse viljatusega seotud geenide sekveneerimine Geenid: ANOS1, AR, AXL, BMP15, BMP4, CASR, CCDC141, CFTR, CLPP, CPEB1, DUOX1, DUOX2, DUOXA2, DUSP6, EIF2B1, EIF2B2, EIF2B4, EIF2B5, EIF4ENIF1, ERCC6, ESR1, ESR2, F2, F5, FEZF1, FGF17, FGF8, FGFR1, FIGLA, FLRT3, FMR1 (k.a. CGG trinukleotiidsed kordusj\u00e4rjestused), FOXE1, FOXL2, FSHB, FSHR, GCM2, GDF9, GHR, GLIS3, GNAS, GNRH1, GNRHR, HARS2, HESX1, HFM1, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":11436,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-25459","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/25459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/comments?post=25459"}],"version-history":[{"count":3,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/25459\/revisions"}],"predecessor-version":[{"id":25862,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/25459\/revisions\/25862"}],"up":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/11436"}],"wp:attachment":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/media?parent=25459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}